Two Olympic weightlifters found guilty of doping at London 2012


Ruslan Nurudinov of Uzbekistan and Mikalai Novikau from Belarus have both been disqualified of any results obtained at he London 2012 Olympic games after both were found to have committed anti-doping violations.

The Anti-Doping Division of the Court of Arbitration for Sport (CAS ADD) reanalysed the athletes’ samples in 2018 to discover the presence of Dehydrochlormethyltesterone (oral turinabol) in both samples, as well as the presence of Stanozolol in Mikalai Novikau’s sample.

Nurudinov had placed forth in the 2012 Olympic Games and had since gone to win Gold medals at the World Championships, the Asian Games and Rio 2016 Olympics. Novikau originally placed eighth at London 2012.

The sole arbitrator confirmed that ‘both athletes committed an anti-doping rule violation and that the appropriate sanction was the disqualification of their results in the competition in question, with all other consequences related thereto as applicable including forfeiture of any medals, points and/or prizes.’

Nurudinov and Novikau were among five weightlifters handed provisional suspensions in December after retests of their samples from London 2012 came back positive.

To view the complete CAS ADD Statement visit here.

You may also like

View All

Tour de France introduces yellow cards to tackle unsportsmanlike conduct

The Tour de France may issue yellow cards for unsportsmanlike behaviour, sparking debate over clarity

Read More

Queensland and federal governments agree on funding deal for the 2032 Games

The Queensland and federal governments have reached an agreement on a funding deal for the 2032 Olympic and Paralympic Games

Read More

WADA publishes stakeholder and athlete feedback from third phase of 2027 Code review

WADA has published its stakeholder feedback from the Third Consultation Phase of the 2027 WADA Code and International Standards Update Process and from the Athlete-Centered Consultation on the same subject

Read More

Newsletter Signup

Please enter your email address below: